questionsmedicales.fr
Maladies de la peau et du tissu conjonctif
Maladies de la peau
Sclérodermie systémique
Sclérodermie diffuse
Sclérodermie diffuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sclérodermie diffuse : Questions médicales les plus fréquentes",
"headline": "Sclérodermie diffuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sclérodermie diffuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-29",
"dateModified": "2025-02-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sclérodermie systémique",
"url": "https://questionsmedicales.fr/mesh/D012595",
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie systémique",
"code": {
"@type": "MedicalCode",
"code": "D012595",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C17.800.784"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse",
"alternateName": "Scleroderma, Diffuse",
"code": {
"@type": "MedicalCode",
"code": "D045743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dinesh Khanna",
"url": "https://questionsmedicales.fr/author/Dinesh%20Khanna",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA."
}
},
{
"@type": "Person",
"name": "Christopher P Denton",
"url": "https://questionsmedicales.fr/author/Christopher%20P%20Denton",
"affiliation": {
"@type": "Organization",
"name": "UCL Division of Medicine, Royal Free Campus, London, UK."
}
},
{
"@type": "Person",
"name": "Ami A Shah",
"url": "https://questionsmedicales.fr/author/Ami%20A%20Shah",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu."
}
},
{
"@type": "Person",
"name": "Susanna Proudman",
"url": "https://questionsmedicales.fr/author/Susanna%20Proudman",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36268143",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/6833078"
}
},
{
"@type": "ScholarlyArticle",
"name": "Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.",
"datePublished": "2022-08-23",
"url": "https://questionsmedicales.fr/article/35997934",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12013-022-01089-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "A rapid fluorescent aptasensor for point-of-care detection of C-reactive protein.",
"datePublished": "2022-06-04",
"url": "https://questionsmedicales.fr/article/35714415",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.talanta.2022.123661"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.",
"datePublished": "2022-07-09",
"url": "https://questionsmedicales.fr/article/35821191",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejim.2022.07.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.",
"datePublished": "2022-06-24",
"url": "https://questionsmedicales.fr/article/35766701",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/1806-9282.20220236"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de la peau et du tissu conjonctif",
"item": "https://questionsmedicales.fr/mesh/D017437"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de la peau",
"item": "https://questionsmedicales.fr/mesh/D012871"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sclérodermie systémique",
"item": "https://questionsmedicales.fr/mesh/D012595"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sclérodermie diffuse",
"item": "https://questionsmedicales.fr/mesh/D045743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sclérodermie diffuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sclérodermie diffuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sclérodermie diffuse",
"description": "Comment diagnostiquer la sclérodermie diffuse ?\nQuels tests sanguins sont utilisés ?\nLes biopsies cutanées sont-elles nécessaires ?\nQuels signes cliniques sont observés ?\nLa radiographie est-elle utile dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=C-Reactive+Protein&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sclérodermie diffuse",
"description": "Quels sont les symptômes principaux ?\nLa fatigue est-elle un symptôme courant ?\nY a-t-il des symptômes respiratoires ?\nComment se manifeste l'atteinte digestive ?\nLes troubles vasculaires sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=C-Reactive+Protein&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sclérodermie diffuse",
"description": "Peut-on prévenir la sclérodermie diffuse ?\nQuels facteurs de risque sont identifiés ?\nLe tabagisme influence-t-il la maladie ?\nL'exposition au froid est-elle un risque ?\nLes infections peuvent-elles aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=C-Reactive+Protein&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sclérodermie diffuse",
"description": "Quels traitements sont disponibles ?\nLes corticostéroïdes sont-ils efficaces ?\nQuelles thérapies physiques sont recommandées ?\nY a-t-il des traitements expérimentaux ?\nComment gérer les symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=C-Reactive+Protein&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sclérodermie diffuse",
"description": "Quelles sont les complications possibles ?\nLa sclérodermie peut-elle affecter le cœur ?\nY a-t-il un risque d'infections ?\nComment la sclérodermie affecte-t-elle les reins ?\nLes complications digestives sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=C-Reactive+Protein&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sclérodermie diffuse",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils significatifs ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nLe stress peut-il aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=C-Reactive+Protein&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la sclérodermie diffuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les antécédents médicaux et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps spécifiques comme les anticorps anti-Scl-70."
}
},
{
"@type": "Question",
"name": "Les biopsies cutanées sont-elles nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être réalisées pour évaluer l'atteinte tissulaire et confirmer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent un durcissement de la peau, des œdèmes et des troubles vasculaires."
}
},
{
"@type": "Question",
"name": "La radiographie est-elle utile dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer les atteintes pulmonaires ou digestives associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent un durcissement de la peau, des douleurs articulaires et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente et peut être liée à l'inflammation et à l'atteinte organique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en raison de l'atteinte pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'atteinte digestive ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se traduire par des reflux, des troubles de la déglutition et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Les troubles vasculaires sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des phénomènes de Raynaud et des ulcères digitaux peuvent se produire."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la sclérodermie diffuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention connue, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont identifiés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et le sexe féminin."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "L'exposition au froid est-elle un risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au froid peut déclencher des symptômes vasculaires comme le phénomène de Raynaud."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent exacerber les symptômes et compliquer la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs, des anti-inflammatoires et des thérapies symptomatiques."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'inflammation, mais leur utilisation doit être prudente en raison des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles thérapies physiques sont recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La kinésithérapie peut aider à maintenir la mobilité et à réduire la douleur articulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les inhibiteurs de la tyrosine kinase sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes cutanés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crèmes hydratantes et des traitements topiques peuvent aider à soulager les symptômes cutanés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des atteintes pulmonaires, cardiaques et rénales, ainsi que des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La sclérodermie peut-elle affecter le cœur ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des arythmies, une hypertension pulmonaire et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison d'une immunité altérée."
}
},
{
"@type": "Question",
"name": "Comment la sclérodermie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertension rénale et une insuffisance rénale, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications digestives sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des reflux, des troubles de la motilité et des malabsorption."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le sexe féminin et certaines expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sclérodermie diffuse survient généralement entre 30 et 50 ans, mais peut toucher d'autres âges."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des solvants organiques et à la silice peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver la maladie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut exacerber les symptômes, bien que son rôle exact dans la sclérodermie ne soit pas clair."
}
}
]
}
]
}
The prognostic role of CRP (C-reactive protein) in gynecological tumors has been previously reported in individual studies, but whether CRP can be used as a separate potential prognostic factor has no...
A systematic search was carried out to find the literature evaluating the predictive role of CRP in the prognosis of gynecological cancer patients. For the purpose of determining the relationship betw...
A total of 19 studies, including 4062 patients, were analyzed retrospectively. The FIGO stage was related to the CRP level (OR = 0.43, 95% CI: 0.19-1.00). Age, lymph node metastasis, and histological ...
CRP may be utilized as a prognostic indicator for a variety of gynecologic malignancies, including cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer....
The acute phase C-reactive protein (CRP) is mainly synthesized and secreted by the liver in a cytokine-mediated response to infection or inflammation and circulates as a pentamer (pCRP) in plasma. Rec...
In this paper, we report on a novel fluorescent aptasensor based on aptamers modified by both nitrogen-doped graphene quantum dots (N-GQDs) and gold nanoparticles (AuNPs) for the detection of C-reacti...
To evaluate the association between C-reactive protein (CRP) and 10-year risk of cardiovascular (CV) events using the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), b...
ERS-RA was calculated in 1,251 "Cardiovascular Obesity and Rheumatic Disease Study (CORDIS)" database patients [(age 60.4(9.3) years; 78% female; disease duration, 11.6(8) years; CDAI, 9(9); CRP, 6.8(...
The mean (SD) 10-year risk of CV events was 12.9% (10). After adjusting for the use of DMARDs and biologics, CRP concentrations were significantly associated with 10-year risk of CV events (coefficien...
In a large cohort of RA patients without previous cardiovascular events, a 20 mg/L increase in CRP concentrations was associated with a 1% increase in 10-year risk of CV events. This suggests that act...
Chronic hepatitis C (CHC) is one of the most important health problems affecting the significant rate of world population and it may lead to cirrhosis and hepatocellular carcinoma. C-reactive protein ...
Patients with CHC infection who visited outpatient and inpatient internal medicine clinics of our institution between January 2021 and December 2021 were enrolled to this retrospective study. CLR of t...
Median CLR of CHC and control subjects was 2.61 (5.13%) and 0.31 (0.37%), respectively. CLR of the CHC group was significantly increased compared to the CLR of the controls (p<0.001). There was a sign...
Increased CLR in patients with CHC may be an alarming finding of liver fibrosis, as CLR is associated with both CHC and hepatic fibrosis....
Life's Essential 8 (LE8) is a score that includes modifiable risk factors for cardiovascular disease. Four health behaviors (diet, physical activity, nicotine exposure and sleep health) and four healt...
We investigate the interactions between C-reactive protein (CRP) and new CRP-binding peptide materials using experimental (biological and physicochemical) methods with the support of theoretical simul...
To assess whether low-grade inflammation, measured by serum high-sensitivity C-reactive protein (hsCRP) levels, is associated with...
A retrospective study....
University-affiliated IVF center....
In the present study, 875 women of normal weight who underwent their first fresh embryo transfer (ET) cycles for IVF treatment were divided into three groups according to serum concentrations of hsCRP...
Serum from women undergoing IVF was collected on days 2-4 of a spontaneous menstrual cycle prior to the commencement of ovarian stimulation....
The IVF outcomes included implantation, biochemical pregnancy, clinical pregnancy, miscarriage and live birth rates....
The women were divided into three groups according to the baseline serum levels of hsCRP as follows: low hsCRP (<1 mg/L; n=517), medium hsCRP (1-3 mg/L; n= 270), high hsCRP (>3 mg/L; n=88). The matern...
Among women of normal weight undergoing their first IVF treatment, it was found that low-grade inflammation was associated with reduced clinical pregnancy and live birth rates following fresh ET cycle...
Interest in using bedside C-reactive protein (CRP) and ferritin levels to identify patients with hyperinflammatory sepsis who might benefit from anti-inflammatory therapies has piqued with the COVID-1...
A prospective, observational cohort study....
Children with sepsis and organ failure in nine pediatric intensive care units in the United States....
Two hundred and fifty-five children were enrolled. Five distinct clinical multi-trajectory groups were identified. Plasma CRP (mg/dL), ferritin (ng/mL), and 31 cytokine levels were measured at two tim...
Group 1 had normal CRP and ferritin levels ( n = 8; 0% mortality); Group 2 had high CRP levels that became normal, with normal ferritin levels throughout ( n = 80; 5% mortality); Group 3 had high ferr...
Bedside CRP and ferritin levels can be used together to distinguish groups of children with sepsis who have different systemic inflammation cytokine responses and mortality risks. These data suggest f...
Social relationships are an important driver of health, and inflammation has been proposed as a key neurobiological mechanism to explain this effect. Behavioral researchers have focused on social rela...